Brief: Outlook Therapeutics Provides Update Following Type A Meeting With FDA
05/03/2026 22:11
March 5 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS PROVIDES UPDATE FOLLOWING TYPE A MEETING WITH FDA REGARDING ONS-5010/LYTENAVA™ (BEVACIZUMAB-VIKG) OUTLOOK THERAPEUTICS INC - EVALUATING REGULATORY OPTIONS FOR ONS-5010/LYTENAVA U.S. APPROVAL OUTLOOK THERAPEUTICS: TO CONTINUE ENGAGING IN DISCUSSIONS WITH FDA TO CLARIFY AGENCY'S VIEWS ON CONFIRMATORY EVIDENCE & APPROPRIATE PATH FORWARD Source text: ID:nGNX49wqvm Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce